Nano-Based Drug Delivery or Targeting to Eradicate Bacteria for Infection Mitigation: A Review of Recent Advances

Yeh, Yuan-Chieh; Huang, Tse-Hung; Yang, Shih-Chun; Chen, Chin-Chang; Fang, Jia‐You

doi:10.3389/fchem.2020.00286

Cited by 279 publications

(150 citation statements)

References 185 publications

(184 reference statements)

Supporting

Mentioning

150

Contrasting

Order By: Relevance

“…This study, as well as prior work suggests that increasing the dose of the drug has little effect on persister cells death 52 . This may explain why many antibiotic loaded nano-systems fail to eradicate established biofilms 53 . The latter nanotechnology strategy is derived from the idea that alteration of the biofilm matrix makes persister cells more vulnerable to conventional drugs.…”

Section: Discussionmentioning

confidence: 99%

Gold nanoclusters augment a fluoroquinolone lethality against biofilm associated persister cells

Bekale

Maria

Cao

et al. 2020

Preprint

View full text Add to dashboard Cite

Persister cells are an important medical concern, leading to the overuse of antibiotics and ultimately contributing to antimicrobial resistance. The use of an adjuvant that augments the antibiotic efficacy has yet to be explored for combating persister cells within biofilm infections. Here we demonstrate a paradigm shift in targeting bacteria in chronic infections by coadministration of a conventional antibiotic with a novel engineered gold nanocluster (AuNC@CPP). AuNC@CPP was found to reduce the minimum biofilm eradication concentration (MBEC) of ofloxacin up to 300-fold (from > 3000 μg/mL to 10 μg/mL). Compared to ofloxacin alone (FLOXIN®Otic), coadministration of ofloxacin with AuNC@CPP induces up to a 10,000-fold reduction in bacterial burden in a validated mouse model of chronic P. aeruginosa of ear infection mimicking chronic suppurative otitis media. The biocompatibility of AuNC@CPP encourages efforts for development as an antibiotic adjunct for combating bacterial biofilm infections.

show abstract

Section: Discussionmentioning

confidence: 99%

Gold nanoclusters augment a fluoroquinolone lethality against biofilm associated persister cells

Bekale

Maria

Cao

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Nanoparticles — defined as particles that range between 1 and 100 nm in diameter — are currently the most widely used vehicles for the delivery of active antimicrobials attached to their surface. Several properties of nanoparticles make them attractive candidates for antimicrobial delivery, including their high surface-to-volume ratio, the possibility of surface functionalisation, and their net-positive charge that allows them to bind to the negatively charged membrane of bacteria [ 17 , 18 ]. Many nanoparticles, especially metallic ones, possess antimicrobial properties themselves, however, for the purpose of this review we will focus on their potential as antimicrobial delivery vehicles.…”

Section: Nanoparticlesmentioning

confidence: 99%

“…Many nanoparticles, especially metallic ones, possess antimicrobial properties themselves, however, for the purpose of this review we will focus on their potential as antimicrobial delivery vehicles. In this section, we will focus on metallic, silica-based or polymer-based nanoparticles [ 2 , 17 , 19 ].…”

Section: Nanoparticlesmentioning

confidence: 99%

Nano-vehicles give new lease of life to existing antimicrobials

Mela

Kaminski

2020

Emerging Topics in Life Sciences

View full text Add to dashboard Cite

Antibiotic resistance has become one of the greatest challenges for modern medicine, and new approaches for the treatment of bacterial infections are urgently needed to avoid widespread vulnerability again to infections that have so far been easily treatable with existing drugs. Among the many approaches investigated to overcome this challenge is the use of engineered nanostructures for the precise and targeted delivery of existing antimicrobial agents in a fashion that will potentiate their effect. This idea leans on lessons learned from pioneering research in cancer, where the targeted delivery of anti-cancer drugs to mammalian cells has been a topic for some time. In particular, new research has demonstrated that nanomaterials can be functionalised with active antimicrobials and, in some cases, with targeting molecules that potentiate the efficiency of the antimicrobials. In this mini-review, we summarise results that demonstrate the potential for nanoparticles, dendrimers and DNA nanostructures for use in antimicrobial delivery. We consider material aspects of the delivery vehicles and ways in which they can be functionalised with antibiotics and antimicrobial peptides, and we review evidence for their efficacy to kill bacteria both in vitro and in vivo. We also discuss the advantages and limitations of these materials and highlight the benefits of DNA nanostructures specifically for their versatile potential in the present context.

show abstract

“…According to Bobo et al in the year 2016 [138], there were 51 nanomedicines approved by the USFDA, including the nanoformulations for antibacterial purposes. Various types of NPs used in the treatment of microbial infections have been discussed in a recent review by Lee et al [139] and Yeh et al [140]. NPs can be designed to carry antibiotics specifically to the pathogen at the site of infection.…”

Section: Nanoparticles As a Delivery Vehicle For Chokismentioning

confidence: 99%

ChoK-ing the Pathogenic Bacteria: Potential of Human Choline Kinase Inhibitors as Antimicrobial Agents

Khalifa

Few

Too

2020

BioMed Research International

View full text Add to dashboard Cite

Novel antimicrobial agents are crucial to combat antibiotic resistance in pathogenic bacteria. Choline kinase (ChoK) in bacteria catalyzes the synthesis of phosphorylcholine, which is subsequently incorporated into the cell wall or outer membrane. In certain species of bacteria, phosphorylcholine is also used to synthesize membrane phosphatidylcholine. Numerous human ChoK inhibitors (ChoKIs) have been synthesized and tested for anticancer properties. Inhibition of S. pneumoniae ChoK by human ChoKIs showed a promising effect by distorting the cell wall and retarded the growth of this pathogen. Comparison of amino acid sequences at the catalytic sites of putative choline kinases from pathogenic bacteria and human enzymes revealed striking sequence conservation that supports the potential application of currently available ChoKIs for inhibiting bacterial enzymes. We also propose the combined use of ChoKIs and nanoparticles for targeted delivery to the pathogen while shielding the human host from any possible side effects of the inhibitors. More research should focus on the verification of putative bacterial ChoK activities and the characterization of ChoKIs with active enzymes. In conclusion, the presence of ChoK in a wide range of pathogenic bacteria and the distinct function of this enzyme has made it an attractive drug target. This review highlighted the possibility of “choking” bacterial ChoKs by using human ChoKIs.

show abstract

Nano-Based Drug Delivery or Targeting to Eradicate Bacteria for Infection Mitigation: A Review of Recent Advances

Cited by 279 publications

References 185 publications

Gold nanoclusters augment a fluoroquinolone lethality against biofilm associated persister cells

Gold nanoclusters augment a fluoroquinolone lethality against biofilm associated persister cells

Nano-vehicles give new lease of life to existing antimicrobials

ChoK-ing the Pathogenic Bacteria: Potential of Human Choline Kinase Inhibitors as Antimicrobial Agents

Contact Info

Product

Resources

About